• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health Reports Fiscal Year 2022 Financial Results

Mar 31, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December...

Tivic Health Systems, Inc. Cuts Component Manufacturing Costs by 70%, Completes Second Key Supplier Qualification

Mar 29, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first...

Tivic Health Systems, Inc. Cuts Component Manufacturing Costs by 70%, Completes Second Key Supplier Qualification

Mar 29, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first...

Tivic Health Systems, Inc. to Report Fiscal Year 2022 Financial Results on March 31st Via Conference Call and Webcast

Mar 24, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the year...

Tivic Cuts Final Assembly Production Costs by 40%, Completes First Key Supplier Qualification

Mar 14, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.